Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
COVID-19
COVID-19 Update
Evaluate Vantage COVID-19 Report
COVID-19 Stories from Evaluate Vantage
Evaluate’s Business Continuity Plan
What We Do
Commercial Intelligence
Products
EvaluatePharma
Evaluate Omnium
Japan Drug Forecasts
European Drug Forecasts
Epi Analyzer
Evaluate Custom Solutions
Evaluate Vantage
News
Analysis
Policy & Pricing
Data Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Careers
Current Vacancies
Contact Us
Sign Up for Evaluate Vantage
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Data Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Targacept
July 29, 2014
Cash-rich Targacept looks beyond Tobacco Road
April 25, 2014
Celgene’s record-breaking deal hangs on phase II data
December 18, 2013
Despite Targacept and other setbacks, Alzheimer’s remains hot
July 23, 2013
In licensing, you don’t always get what you pay for
November 30, 2012
Big beasts exert influence as biotech comes back from the dead
September 18, 2012
Has off-target Targacept reached the end of the road?
July 19, 2012
Event – Glaxo endorsement puts focus on Amicus phase III result and more
March 20, 2012
Therapeutic focus - Hopes fading for nicotinic receptors as Astra pill flunks
February 29, 2012
Abbott-Galapagos deal ranks amongst largest for phase II asset
January 23, 2012
Key data read outs and patent hearings in the first half of 2012
January 19, 2012
Big pharma's key events for the next six months
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
July 29, 2020
Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2020
April 16, 2020
Evaluate Vantage COVID-19 Report
Editor's Picks
October 20, 2020
Finding the next Vertex
October 15, 2020
Clinical setback lays bare Vertex’s weakness
October 15, 2020
SITC 2020 – embargo snafu triggers the first movers
October 19, 2020
Biopharma buyouts still pricey
September 30, 2020
More biotechs test the third way to market
